Table 2.
The relationship between ELN expression in tumor tissue and clinicopathological characteristics
| Characteristic | ELN high expression | ELN low expression | P value |
|---|---|---|---|
| Number of patients | 71 | 109 | |
| Age (mean ± SD) | 60.15 ± 8.36 | 60.34 ± 10.13 | 0.894 |
| BMI (median, IQR) | 22.99 (21.02, 24.89) | 22.84 (20.38, 24.98) | 0.641 |
| Sex, n (%) | 0.565 | ||
| Female | 16 (8.9%) | 30 (16.7%) | |
| Male | 55 (30.6%) | 79 (43.9%) | |
| Tumor infiltration pattern, n (%) | 0.081 | ||
| INFa | 11 (6.1%) | 25 (13.9%) | |
| INFb | 15 (8.3%) | 29 (16.1%) | |
| INFc | 35 (19.4%) | 33 (18.3%) | |
| N/A | 10 (5.6%) | 22 (12.2%) | |
| Lymphatic infiltration, n (%) | 0.078 | ||
| Negative | 34 (18.9%) | 68 (37.8%) | |
| Positive | 37 (20.6%) | 41 (22.8%) | |
| Venous infiltration, n (%) | 0.219 | ||
| Negative | 48 (26.7%) | 84 (46.7%) | |
| Positive | 23 (12.8%) | 25 (13.9%) | |
| Nerve infiltration, n (%) | 0.718 | ||
| Negative | 17 (9.4%) | 30 (16.7%) | |
| Positive | 54 (30%) | 79 (43.9%) | |
| T classification, n (%) | 0.121 | ||
| T1 | 2 (1.1%) | 8 (4.4%) | |
| T2 | 7 (3.9%) | 20 (11.1%) | |
| T3 | 26 (14.4%) | 42 (23.3%) | |
| T4 | 36 (20%) | 39 (21.7%) | |
| N classification, n (%) | 0.002 | ||
| N0 | 15 (8.3%) | 35 (19.4%) | |
| N1 | 7 (3.9%) | 29 (16.1%) | |
| N2 | 20 (11.1%) | 21 (11.7%) | |
| N3 | 29 (16.1%) | 24 (13.3%) | |
| pTNM stage, n (%) | 0.003 | ||
| I | 6 (3.3%) | 17 (9.4%) | |
| II | 14 (7.8%) | 42 (23.3%) | |
| III | 51 (28.3%) | 50 (27.8%) | |
| Metastatic lymph node ratio, n (%) | <0.001 | ||
| <0.3 | 45 (25%) | 95 (52.8%) | |
| ≥0.6 | 7 (3.9%) | 5 (2.8%) | |
| ≥0.3, <0.6 | 19 (10.6%) | 9 (5%) | |
| Borrmann type, n (%) | 0.616 | ||
| Borrmann 1 | 6 (3.3%) | 9 (5%) | |
| Borrmann 2 | 16 (8.9%) | 33 (18.3%) | |
| Borrmann 3 | 41 (22.8%) | 59 (32.8%) | |
| Borrmann 4 | 8 (4.4%) | 8 (4.4%) | |
| Lauren classification, n (%) | 0.626 | ||
| Diffuse | 29 (16.1%) | 35 (19.4%) | |
| Intestinal | 18 (10%) | 31 (17.2%) | |
| Mixed | 14 (7.8%) | 22 (12.2%) | |
| Unknown | 10 (5.6%) | 21 (11.7%) | |
| Family genetic history, n (%) | 1.000 | ||
| No | 64 (35.6%) | 99 (55%) | |
| Yes | 7 (3.9%) | 10 (5.6%) | |
| Tumor location, n (%) | 0.058 | ||
| Entire stomach | 5 (2.8%) | 1 (0.6%) | |
| Lower third | 34 (18.9%) | 63 (35%) | |
| Middle and upper third | 32 (17.8%) | 45 (25%) | |
| HER2 expression, n (%) | 0.109 | ||
| Negative | 57 (31.7%) | 98 (54.4%) | |
| Positive | 14 (7.8%) | 11 (6.1%) | |
| CEA, n (%) | 0.473 | ||
| >5 ng/ml | 7 (3.9%) | 16 (8.9%) | |
| ≤5 ng/ml | 64 (35.6%) | 93 (51.7%) | |
| CA19‐9, n (%) | 0.934 | ||
| >37 U/ml | 8 (4.4%) | 14 (7.8%) | |
| ≤37 U/ml | 63 (35%) | 95 (52.8%) | |
| CA72‐4, n (%) | 0.989 | ||
| >6 U/ml | 18 (10%) | 29 (16.1%) | |
| ≤6 U/ml | 53 (29.4%) | 80 (44.4%) |
Histological type, T classification, N classification, and pTNM classification were according to the AJCC 8th edition of the Cancer Staging Manual of the American Joint Committee on Cancer. Vascular infiltration, nerve infiltration, and lymphatic infiltration were determined according to the postoperative pathology report. Lauren classification is based on the histology, morphology, and biological characteristics of GC.
IQR, interquartile range. Statistically significant P values are marked in bold font.